Cite
APA Citation
Banerjee, S., Oaknin, A., Sanchez-Simon, I., Salgado, A. C., Patel, S. P., Oza, A., Das, M., Kourtesis, P., Ascierto, M. L., & Diamond, J. R. (n.d.). 518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers. International journal of gynecological cancer, 30, A86–A87. http://access.bl.uk/ark:/81055/vdc_100144717185.0x00001b